Cycle Vita™ - dedicated support for you

We know that life-changing treatments need a support system that is tailored to the unique challenges you might be facing. That’s why we created Cycle Vita, our dedicated patient support* program, where you can find one-to-one support on HARLIKU™ (nitisinone) Tablets and alkaptonuria (AKU), including:

Bridge Icon

Bridge Program

If you are 18 years of age or older and have commercial insurance, a free supply of HARLIKU is available to help you begin therapy immediately. Meanwhile, we will secure appropriate Benefit Verification and assist your healthcare provider with Prior Authorization, as necessary.

The Bridge Program may also be requested if you experience a temporary disruption in therapy due to insurance coverage. Bridge duration is driven by insurance coverage and the active collaboration of your clinic.

Dollar Icon

$0 Co-Pay Assistance Program

Commercially insured eligible patients may pay as little as $0.

Medication Form Icon

Reimbursement Research Support

The Cycle Vita team are experts in assisting with securing coverage, and can support you throughout the process, including Benefit Investigations and Prior Authorization assistance. Where an appeal is needed, Cycle Vita will work with your insurer to understand the requirements and help with any reimbursement gaps.

Doctor Icon

Continuous Clinical Product Education

Cycle Vita provides you with product support to help manage every aspect of the HARLIKU therapeutic routine, such as onboarding onto therapy, clinical education and ongoing support with adherence. Additional support with nutrition and managing the physical aspects** of AKU are available when necessary.

Throughout your HARLIKU treatment, you can expect to hear from two different types of specialists at Cycle Vita.

Doctor Chat Icon

Clinical Education Managers

Provide you with clinical education, product support, and nutritional support (when necessary).*

Specialist Team Icon

Access Specialists

Help you access HARLIKU through enrollment, financial and pharmacy support.*

The Cycle Vita Team

Your friendly and familiar Cycle Vita team is here to provide product and process support* at every step. The Cycle Vita team is just a phone call away.

Enroll nowNeed help? Get in touch with Cycle Vita888-360-8482

*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at 888-360-8482.

**Please consult your healthcare provider before beginning any new exercise program. Cycle Pharmaceuticals accepts no liability for injuries or health issues arising from participation in these activities.

HALIKU Logo
HALIKU Logo

Indications

HARLIKU™ (nitisinone) Tablets is indicated for the reduction of urine homogentisic acid (HGA) in adult patients with alkaptonuria (AKU).

Important Safety Information

Do not take HARLIKU if you are allergic to nitisinone or any of the other ingredients. Tell your healthcare provider about any health problems, and if you are pregnant or planning to become pregnant and/or breastfeeding, before starting treatment.

Serious Adverse Reactions:

Eye Symptoms and Skin Changes Due To Elevated Plasma Tyrosine Levels:

Inadequate restriction of tyrosine and phenylalanine intake can result in elevated levels of plasma tyrosine, which may lead to keratitis (eye problems) and hyperkeratotic plaques (thickening of the skin on the soles and palms).

    • Your healthcare provider will obtain a slit-lamp examination prior to initiating HARLIKU treatment, regularly during treatment and may reexamine you if you develop symptoms or if you develop high plasma tyrosine levels.
    • Your HARLIKU treatment may be temporarily interrupted until symptoms have resolved.

Changes in Blood Profile:

    • You may develop leukopenia (reduction in the number of white blood cells, which form part of the immune system) and severe thrombocytopenia (abnormally low levels of platelets, which help the blood to clot).
    • Your healthcare provider will monitor platelet and white blood cell counts during HARLIKU therapy.

Common Adverse Reactions:

The most common adverse reactions (≥1%) reported in patients with AKU taking nitisinone in the clinical trials were elevated tyrosine levels, low platelets (thrombocytopenia) and inflammation of the cornea, eye irritation, eye pain and photophobia (keratitis).

Drug Interactions:

Nitisinone can interfere with the effect of other medicines. Tell your healthcare provider or pharmacist if you are taking, have recently taken or might take any other medicines.

Use in Specific Populations:

Pregnancy: The safety of this medicine has not been studied in pregnancy. Tell your healthcare provider immediately if you become pregnant or are planning to become pregnant.

Lactation: The safety of this medicine has not been studied in breastfeeding women. Tell your healthcare provider immediately if you plan to breastfeed.

Pediatric Use: The safety of this medicine have not been studied in pediatric patients with AKU.

Geriatric Use: Clinical studies of HARLIKU did not include a sufficient number of patients 65 years of age and older, to determine whether they respond differently from younger adult patients. Elderly patients should be cautious reflecting any decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

If you get any side effects, talk to your healthcare provider. This includes possible side effects not listed above.

For more detailed information, please refer to the full Prescribing Information at harliku.com/pi/

To report SUSPECTED ADVERSE REACTIONS, contact Cycle Pharmaceuticals at 1-855-831-5413, or the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch.

HARLIKU™ (nitisinone) Tablets

© 2026 Cycle Pharmaceuticals Limited. All rights reserved.

HARLIKU™ and Cycle Vita™ are trademarks of Cycle Pharmaceuticals Limited in the United States.

Contact us

@CycleVitaUSA

@CycleVitaUSA